Resource Logo
NLM AIDSLINE

IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses.




 

Br J Pharmacol. 1999 Jul;127(6):1295-304. Unique Identifier : AIDSLINE

Interleukin-12 (IL-12) is a pivotal cytokine in driving the immune system towards a T helper (Th)1 type response and preventing a Th2 type immune profile. Therefore, IL-12 is indispensable in the defense against certain, mainly intracellular pathogens, but overproduction of this cytokine is crucially involved in the etiology of several inflammatory and autoimmune diseases. Hence, IL-12 is an ideal target for pharmacological intervention in the therapy of autoimmune and inflammatory diseases. The production of IL-12 and a resultant Th1 type immune response can be suppressed with several pharmacological approaches including modulation of intracellular cyclic AMP levels, glucocorticoids and nuclear factor-kappaB inhibition. IL-12 responsiveness may be inhibited using anti-IL-12 antibodies, soluble IL-12 receptors or the IL-12 p40 homodimer. Exploitation of these approaches may provide novel means for the experimental therapy of a variety of pathophysiological states.

JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL Animal Autoimmune Diseases/*DRUG THERAPY/METABOLISM Human Inflammation/*DRUG THERAPY/METABOLISM Interleukin-12/*ANTAGONISTS & INHIB/BIOSYNTHESIS Th1 Cells/DRUG EFFECTS/IMMUNOLOGY Th2 Cells/DRUG EFFECTS/IMMUNOLOGY



 




Information in this article was accurate in December 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.